Diagnosis and Management of Advanced Prostate Cancer
A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".
Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 443
Special Issue Editor
Interests: urogenital malignancies; advanced prostate cancer; kidney cancer; rare disease subtypes; clinical trials; multidisciplinary approach; tailored therapy; immunotherapy; toxicity management; Lu-PSMA
Special Issue Information
Dear Colleagues,
Prostate cancer represents the most common malignancy among men in western countries. The therapeutical landscape of prostate cancer has changed enormously in the last decade, including improvements in imaging modalities, genomic profiling, development of new targeted therapies, their sequencing, and the multimodality approach. In this Special Issue, we will focus on innovations in prostate cancer management, starting with developments in imaging that will influence and shape the prostate cancer treatment strategy. The role of genomic profiling is increasing and influencing the individualization of therapy in real clinical practice. Getting to know the disease biology is of utmost importance for any further steps. Advances in biomarker assessment will optimize future therapeutical decisions to improve the outcome of prostate cancer. New findings in the field of systemic therapy in both metastatic hormone-sensitive and castration-resistant cancer are more than welcome. We intend for this Special Issue to be informative for all prostate cancer researchers.
Dr. Hana Študentová
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- innovations in prostate cancer
- imaging
- biomarkers
- circulating tumor DNA
- genomic profiling
- local treatment
- systemic therapy
- metastatic hormone sensitive
- metastatic castration resistant
- individulized therapy
